Dopamine Aptamer Reduces Cognitive Dysfunction in Schizophrenia Model
Author Information
Author(s): Matthew R. Holahan, Dan Madularu, Erin M. McConnell, Ryan Walsh, Maria C. DeRosa
Primary Institution: Carleton University
Hypothesis
The dopamine-binding DNA aptamer will mitigate MK-801-induced cognitive deficits when injected into the nucleus accumbens.
Conclusion
The study found that the dopamine aptamer effectively reversed MK-801-induced cognitive deficits in rats without impairing locomotor activity.
Supporting Evidence
- The dopamine aptamer reversed MK-801-induced elevation in lever pressing to levels seen in untreated rats.
- No significant differences in locomotor activity were observed between groups.
- Immunohistochemical analysis showed reduced levels of phosphorylated tyrosine hydroxylase in the aptamer-treated group.
Takeaway
Researchers tested a special DNA that can stick to dopamine in the brain and found it helped rats think better after being given a drug that usually makes them confused.
Methodology
Rats were trained to press levers for rewards, then injected with either a dopamine aptamer or control substances before being treated with MK-801 to assess cognitive function.
Potential Biases
Potential bias in the selection of control groups and the interpretation of behavioral results.
Limitations
The study was conducted on a small sample size of male Long Evans rats, which may limit the generalizability of the findings.
Participant Demographics
Male Long Evans rats, n=31.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website